2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
58
Unknown
13
Terminated
8
Active not recruiting
5
Recruiting
4
Withdrawn
2
Suspended
1
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
73
Breast Neoplasms
70
Colorectal Neoplasms
39
Prostatic Neoplasms
37
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
25
Stomach Neoplasms
20
Carcinoma, Hepatocellular
20
Uterine Cervical Neoplasms
19
Pancreatic Neoplasms
15
Anxiety Disorders
15
Leukemia, Myeloid, Acute
14
Hematologic Neoplasms
13
Colonic Neoplasms
13
Brain Neoplasms
13
Urinary Bladder Neoplasms
12
Lymphoma, Follicular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Head and Neck Neoplasms
11
Esophageal Neoplasms
10
Diabetes Mellitus
10
Ovarian Neoplasms
9
Melanoma
9
Liver Neoplasms
9
Sarcoma
8
Rectal Neoplasms
8
Pulmonary Disease, Chronic Obstructive
8
Multiple Myeloma
8
Esophageal Squamous Cell Carcinoma
8
Disease
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Neurotoxicity Syndromes
×
Clear all
NCT06950190
2025-08-12
(ECCPC)
Ellis Medicine
Phase 3
Enrolling by invitation
100 enrolled